MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
01 nov. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
31 oct. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
16 oct. 2023 16h00 HE
|
MBX Biosciences, Inc.
MBX 2109 was generally well-tolerated across all dosing cohorts MBX 2109 pharmacokinetics reflected the intended prodrug design and support once-weekly dosing MBX 2109 increased albumin adjusted...
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
09 oct. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
03 oct. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 03, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
11 sept. 2023 08h00 HE
|
MBX Biosciences, Inc.
MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium and suppressed endogenous PTH(1-84) CARMEL, Ind., Sept. 11, 2023 (GLOBE NEWSWIRE) -- MBX...
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
29 août 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
07 août 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
10 juil. 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Jefferies Healthcare Conference
24 mai 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...